Research programme - T-cell receptor based cancer therapeutics - BioNTech/Scancell

Drug Profile

Research programme - T-cell receptor based cancer therapeutics - BioNTech/Scancell

Alternative Names: Research programme - T-cell based cancer therapeutics - Scancell/BioNTech; Research programme - T-cell receptor based cancer therapeutics - Scancell/BioNTech; Research programme - T-cell receptor based therapeutics - Scancell/BioNTech

Latest Information Update: 13 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioNTech; Scancell
  • Class Antineoplastics; Immunotherapies
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 09 Feb 2018 Scancell files patent applications for Moditope® immunotherapy platform in Australia, Brazil, Canada, China, Hong Kong, Japan, South Korea, South Africa and USA
  • 09 Feb 2018 Scancell receives intention to grant patent for Moditope® immunotherapy platform from European Patent Office
  • 09 Jan 2018 BioNTech and Scancell enter into research collaboration for the development of cancer immunotherapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top